<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085562</url>
  </required_header>
  <id_info>
    <org_study_id>0201243</org_study_id>
    <nct_id>NCT04085562</nct_id>
  </id_info>
  <brief_title>Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.</brief_title>
  <official_title>Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension is highly prevalent in hemodialysis (HD) patients and leads to increased
      morbidity and mortality due to cardiovascular disease(CVD). Left ventricular hypertrophy
      (LVH) is both a manifestation of hypertension caused end-organ damage and an independent risk
      factor for CVD. Evidence shows that Beta-blockers, especially of low dialyzability decrease
      risk of CVD and mortality. Calcium channel blockers (CCBs) were also shown to effectively
      control BP in the volume expanded state and reduce cardiovascular disease risk. Asymmetric
      dimethyl arginine (ADMA) is a uremic toxin that decreases NO synthesis and is correlated to
      LVH, carotid intimal thickness (CIT), CVD, and mortality. Amlodipine is shown in one study to
      significantly reduce ADMA level in HD patients. The purpose of this study is to determine the
      effect of calcium channel blocker Amlodipine compared to Beta-blocker Bisoprolol on
      regression of LVH, reduction of ADMA plasma level and on BP control among hypertensive
      patients on HD.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left Ventricular Mass Index</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ADMA Blood level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Hypertension, Renal</condition>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertensive patients on dialysis receiving Amlodipine 5-10 mg tablet daily alone or as part of antihypertensive regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bisoprolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertensive patients on dialysis receiving Bisoprolol 5-10 mg tablet daily alone or as part of antihypertensive regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol Fumarate 5-10 mg</intervention_name>
    <description>Bisoprolol as antihypertensive drug in patients on hemodialysis</description>
    <arm_group_label>Bisoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5-10 mg</intervention_name>
    <description>Amlodipine as antihypertensive drug in patients on hemodialysis</description>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  On maintenance hemodialysis 3 times weekly for at least 3 months.

          -  Hypertensive as determined by predialytic BP &gt; 140/ 90, post-dialytic &gt; 130/80,
             home-measured BP &gt;140/90 and/or on antihypertensive medication.

        Exclusion Criteria:

          -  History of malignancy.

          -  History of significant valvular heart disease.

          -  Chronic congestive heart failure.

          -  History of coronary artery disease.

          -  Ongoing atrial fibrillation.

          -  Known drug abuse.

          -  Known contraindication to Bisoprolol or Amlodipine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Youssef, BSPharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noha El-khodary, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of pharmacy, Damanhour University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maged Wasfy, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of pharmacy, Damanhour University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hesham Elghonemy, Phd</last_name>
    <role>Study Director</role>
    <affiliation>University of Alexandria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>El Mowassat University hospital</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 8, 2019</study_first_submitted>
  <study_first_submitted_qc>September 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>April 19, 2020</last_update_submitted>
  <last_update_submitted_qc>April 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Ahmed Youssef</investigator_full_name>
    <investigator_title>Teaching assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hypertension, Renal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data underlying results.</ipd_description>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Starting 6 months after publication.</ipd_time_frame>
    <ipd_access_criteria>Controlled access to data.
Requests are made to the PI.
Requests are reviewed and answered by the PI.
Data will be provided through E-mail.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

